

## Presentation of the Liflow<sup>®</sup> solution at the AI Action Summit event in Paris, as part of AI Action Week

- A strategic presence at the heart of AI innovation in healthcare
- Exchanges with international delegations and the Minister for Health and Access to Care

Montpellier, France, February 12, 2025. Intrasense (ISIN: FR0011179886 – Mnémo : ALINS), [French expert in medical imaging solutions enhanced by AI assisting and securing diagnosis, decision-making and therapeutic follow-up](#), took part in the Side Event AI Action Summit, an event held on February 11, 2025 at the Grand Palais in Paris, as part of AI Action Week.

On this occasion, **Alexandre Salvador, Intrasense's CEO**, says: « *We are very proud to have been invited to take part in such a high-profile event and to be able to present our Liflow<sup>®</sup> solution in front of the international AI Action Week delegation. For several years, we have been committed to offering cutting-edge solutions to optimize the work of healthcare professionals and facilitate patient care. In just 1 year, our Liflow<sup>®</sup> artificial intelligence-enhanced solution has been recognized and acclaimed by many key players in the sector. Our participation in this international event was therefore, once again, an opportunity to demonstrate the relevance of our solution and, more generally, to demonstrate how artificial intelligence is transforming medical imaging and improving patient care.* »

### A strategic presence at the heart of AI innovation in healthcare

Held from February 6 to 11, 2025, AI Action Week positions Paris as a global center for reflection and innovation in artificial intelligence. This international event brings together researchers, companies, decision-makers and civil society to explore the challenges and opportunities of AI.

As part of the Summit's Side Events, organized by Parisanté Campus in partnership with Sanofi, Business OECD and French Healthcare Association Intrasense took part in an exceptional learning expedition on February 11 on "Challenges of AI in healthcare".

The event welcomed high-level international delegations as well as Yannick Neuder, the French Minister for Health and Access to Care, to highlight French excellence in AI applied to healthcare. As part of the event, Intrasense was given exhibition space and a presentation platform to demonstrate its innovative solutions to industry experts and institutional decision-makers. The opportunity for the Company to highlight its technological innovations designed to improve patient care through AI applied to medical imaging.

### Liflow<sup>®</sup>: AI for oncology diagnostics

Committed to the transformation of medical imaging, Intrasense develops AI-based solutions that optimize diagnosis, accelerate clinical decision-making and improve patient follow-up. By putting AI at

the service of healthcare professionals, Intrasense is actively involved in building more accurate, efficient and humane medicine.

At the event, Intrasense, Guerbet's digital subsidiary, presented Liflow<sup>®</sup> 3.0<sup>1</sup>, a next-generation oncology imaging solution optimizing the follow-up of cancer patients and thus improving clinical decision-making. Designed to facilitate and secure the analysis of CT-TAP scans, the solution is enriched with "multi-organ" artificial intelligence algorithms. Version 3.0<sup>1</sup> of Liflow<sup>®</sup> integrates three AIs dedicated to lung, liver and bone lesions.

Winner of the "Innovation Prize" at the French Radiology Days (Journées Francophones de la Radiologie) 2024, Liflow<sup>®</sup> is based on outstanding medical and scientific expertise. Developed in collaboration with the CHU d'Angers and the Institut Gustave Roussy - Europe's leading cancer center and one of the world's top five cancer hospitals<sup>2</sup> - Liflow<sup>®</sup> recently received funding of 5.9 million from France 2030, as part of a BPI France call for projects.

## About Intrasense

**French expert in medical imaging since 2004, Intrasense develops and markets software platforms in 40 countries to facilitate and secure diagnosis, decision-making and therapeutic follow-up.**

Myrian<sup>®</sup>, an advanced visualization solution for radiology, provides 1,200 healthcare establishments with clinical applications to assist in the interpretation of all types of images. Since 2021, Intrasense has been developing Liflow<sup>®</sup>, a new multidisciplinary and collaborative platform dedicated to oncology, to optimize patient care and follow-up. A digital subsidiary of the Guerbet Group since June 2023, Intrasense continues to enrich its solutions by integrating artificial intelligence algorithms in medical imaging. Its teams work closely with healthcare professionals to help save lives.

**Further information at [www.intrasense.fr](http://www.intrasense.fr)**

## Contacts

### INTRASENSE

#### Communications Officer

Salomé Sylvestre

Phone: +334 67 13 01 30

[investisseurs@intrasense.fr](mailto:investisseurs@intrasense.fr)

### SEITOSEI.ACTIFIN

#### Analyst & Investor Relations

Foucauld Charavay

Phone: +336 37 83 33 19

[intrasense@seitosei-actifin.com](mailto:intrasense@seitosei-actifin.com)

#### Press Relations

Isabelle Dray

Phone: +331 56 88 11 29

[isabelle.dray@seitosei-actifin.com](mailto:isabelle.dray@seitosei-actifin.com)

<sup>1</sup> Version 3.0 under development, not CE marked

<sup>2</sup> Statista and Newsweek study (2025) : « World's Best Specialized Hospitals 2025 - Oncology ». Available at: <https://r.statista.com/en/healthcare/worlds-best-specialized-hospitals-2025/ranking>